Testing new drug combinations for advanced lung cancer patients
A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
This study is looking at how two medications, MLN0128 and CB-839, can help people with advanced non-small cell lung cancer who have a tough prognosis, especially those with certain genetic changes in their tumors, to see if these drugs can work better together to fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10673018 on NIH RePORTER |
What this research studies
This research investigates the effects of two drugs, MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat), on patients with advanced non-small cell lung cancer (NSCLC) who have poor prognoses. The study focuses on specific genetic mutations in tumors that may affect how these drugs work together to inhibit cancer growth. By targeting both glycolysis and glutamine metabolism, the research aims to overcome treatment resistance and improve outcomes for patients. Participants will receive these medications to assess their safety and effectiveness in this context.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer, particularly those with specific genetic mutations.
Not a fit: Patients with early-stage lung cancer or those whose tumors do not have the targeted genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced lung cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach may yield significant results.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Paik, Paul K — Sloan-Kettering Inst Can Research
- Study coordinator: Paik, Paul K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.